Unlike the previous DNA sequencing tests that found no targetable alterations, BostonGene’s comprehensive whole exome and transcriptome analysis showed several novel findings, including elevated expression of FGFR1/2 and CDK6 compared to patients with a similar diagnosis. BostonGene’s solution helped to demonstrate availability of suitable clinical trials with novel targeted treatment regimes. “When my doctor called to say there was an option to be enrolled in a clinical trial, I felt such excitement and hope,” Anna recalls. Since June 2020, Anna has been treated with Abemaciclib (Verzenio™), a CDK4/6 inhibitor. Scans from February 2021 show that the pulmonary nodules and masses are shrinking, representing decreased metastatic disease. Anna remains committed to her treatment as long as it works.
“We went from doing nothing to treat my cancer, to having an alternative treatment option that has slowed the cancer growth. Not only did BostonGene provide more information about my cancer, they provided me with hope,” Anna says.